May 30, 2021 11:59:38 pm
Fortis Hospital, Mohali, on Sunday administered the ‘antibody cocktail’ therapy to a 72-year-old Covid-19 positive patient, who has a known history of diabetes along with chronic kidney disease. The patient had tested positive for Covid-19 two days ago. He was administered one dose of the cocktail intravenously and is reportedly stable, post infusion.
The ‘anti-body cocktail therapy’ is for those above the age of 65, who are isolating at home, have an SpO2 of 93, require no oxygen support but are at risk of developing a severe form of the infection on account of their co-morbidities — such as obesity, diabetes, liver disease, heart ailments, and chronic lung disease. It can also be administered to those suffering from an immunocompromising condition or those with weakened immunity on account of immune suppressive treatment.
Dr. Zafar Ahmed, senior consultant (critical care), Pulmonology and Chest and Sleep Medicine, of Fortis Hospital Mohali said just like antibodies, which are proteins generated by the body to fight diseases, monoclonal antibodies are ‘artificially created in the lab’. In this cocktail, Casirivimab and Imdevimab are monoclonal antibodies that specifically block the spike protein of SARS-CoV-2, thereby preventing the Covid attachment and entry into human cells. Six-hundred grams of each are mixed in the form of a cocktail. This is another very important step that has been taken by the medical community to effectively combat the pandemic and help people recover faster.
On Saturday, Fortis Healthcare announced that two doses of Roche India’s Antibody Cocktail (Casirivimab and Imdevimab), distributed by Cipla Ltd, was available for administration to patients with mild and moderate Covid-19 infection.
📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines
- The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.